Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228213 | 0.81 | NOTUM (0.54) | NOTUMHSD17B3BRD4CYP2D6CYP2C9 | |
| SCHEMBL1477941 | 0.81 | NOTUM (0.46) | NOTUMHSD17B3 | |
| SCHEMBL859611 | 0.81 | LMNA (0.48) | NOTUMHSD17B3 | |
| SCHEMBL9183671 | 0.80 | P2RX4 (0.53) | NOTUM | |
| SCHEMBL4798373 | 0.73 | HSD17B3 (0.71) | NOTUMHSD17B3 | |
| SCHEMBL7713210 | 0.73 | NOTUM (0.49) | NOTUMHSD17B3 | |
| SCHEMBL4798382 | 0.73 | HSD17B3 (0.71) | NOTUMHSD17B3 | |
| SCHEMBL6197218 | 0.69 | NOTUM (0.57) | NOTUMHSD17B3BRD4 | |
| SCHEMBL6198391 | 0.69 | HSD17B3 (0.53) | NOTUMHSD17B3BRD4 | |
| SCHEMBL2193457 | 0.69 | NOTUM (0.57) | NOTUMHSD17B3BRD4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | claimed |
| EP-1499311-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-04 | — | — | EP | claimed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | claimed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090105285-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-2023956-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| WO-2007131689-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105285-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | BRAF, RAF1, MTOR | NOTUM 3906/4885HSD17B3 3135/4885BRD4 1046/4885 |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | BRAF, RAF1, ARAF | NOTUM 2783/4885HSD17B3 1699/4885BRD4 403/4885 |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | RAF1, BRAF, ARAF | NOTUM 3690/4885HSD17B3 4256/4885BRD4 303/4885 |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | BRAF, RAF1, MTOR | NOTUM 3906/4885HSD17B3 3135/4885BRD4 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.